Bone Biologics (NASDAQ:BBLG) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Bone Biologics (NASDAQ:BBLG) posted its earnings results on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.04), FiscalAI reports.

Bone Biologics Stock Performance

Shares of Bone Biologics stock traded down $0.02 during trading hours on Friday, reaching $0.66. 167,161 shares of the company were exchanged, compared to its average volume of 142,196. The firm has a market cap of $1.19 million, a PE ratio of -0.29 and a beta of 0.92. Bone Biologics has a 1 year low of $0.62 and a 1 year high of $4.13. The stock’s fifty day moving average is $1.19 and its 200 day moving average is $1.25.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Bone Biologics stock. DRW Securities LLC raised its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 34.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bone Biologics in a research note on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.